Provided by Tiger Trade Technology Pte. Ltd.

Rigel Pharmaceuticals

45.11
-0.7800-1.70%
Post-market: 45.110.00000.00%19:58 EDT
Volume:542.01K
Turnover:24.54M
Market Cap:842.65M
PE:2.74
High:46.21
Open:45.63
Low:44.51
Close:45.89
52wk High:52.24
52wk Low:24.95
Shares:18.68M
Float Shares:14.85M
Volume Ratio:1.34
T/O Rate:3.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):16.45
EPS(LYR):19.48
ROE:126.90%
ROA:14.95%
PB:1.98
PE(LYR):2.32

Loading ...

Rigel Pharmaceuticals is Maintained at Neutral by Piper Sandler

Dow Jones
·
Aug 18

Rigel Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 15

H.C. Wainwright Reaffirms Their Buy Rating on Rigel (RIGL)

TIPRANKS
·
Aug 14

Rigel Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $85 from $57

THOMSON REUTERS
·
Aug 14

Rigel Says Breast Cancer Drug Veppanu Now Available in US, Puerto Rico

MT Newswires Live
·
Aug 13

Rigel Announces Availability of Veppanu™ (Vepdegestrant) for Patients with Er+/Her2-, Esr1-Mutated Advanced or Metastatic Breast Cancer

THOMSON REUTERS
·
Aug 13

Rigel Pharmaceuticals, - Veppanu Available at $29,400 Per 30-Day Supply in U.S. and Puerto Rico

THOMSON REUTERS
·
Aug 13

Rigel Pharmaceuticals price target raised to $83 from $81 at Citi

TIPRANKS
·
Aug 06

Rigel Pharmaceuticals Posts Corporate Deck Highlighting Veppanu In-License and Commercial Launch Plan

Reuters
·
Aug 05

Rigel Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Rigel Pharmaceuticals Q2 Revenue Rises on Strong Product Demand

Reuters
·
Aug 05

Rigel Q2 FY26 Net Income Falls to $17.3 Million; Revenue Drops to $78.7 Million

Reuters
·
Aug 05

Rigel Pharmaceuticals Q2 EPS $0.88 Beats $0.62 Estimate, Sales $78.700M Beat $69.463M Estimate

Benzinga Earnings
·
Aug 05

Rigel Reports Second Quarter 2026 Financial Results

THOMSON REUTERS
·
Aug 05

Rigel Pharmaceuticals Inc : Jefferies Raises Target Price to $55 from $50

THOMSON REUTERS
·
Jul 27

Rigel Pharmaceuticals Grants 13,375 Inducement Rsus to Six New Hires

Reuters
·
Jul 07

Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 07

Rigel Pharmaceuticals - Appoints Alison L. Hannah as Executive Vice President and Chief Medical Officer Effective July 1, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 02

Rigel Names Board Member Alison Hannah Chief Medical Officer, Replacing Lisa Rojkjaer

Reuters
·
Jul 01

Rigel Appoints Board Member Alison L. Hannah, M.d. as Chief Medical Officer

THOMSON REUTERS
·
Jul 01